• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CardioVascular BioTherapeutics Completes Pre-Clinical Stroke Research

Posted on: Thursday, 12 July 2007, 09:19 CDT

CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced the completion of its pre-clinical research program to assess the effects of its protein-based drug candidate, CVBT-141F, in reducing brain damage due to stroke. Results from three independent animal studies, summarized in the accompanying graphic, demonstrated that CVBT 141F significantly reduced the stroke-affected area in the brain as compared to control groups, while treated animals had significantly less neurological defects as assessed by several behavioral tests.

Dr. Thomas J. Stegmann, M.D., co-founder and chief medical officer, CVBT, stated, "We were encouraged by the magnitude of the reduction of the area of stroke damage in the animals that received CVBT-141F from initial pre-clinical trials. Should such efficacy be demonstrated moving into human trials, CVBT 141F holds promise to serve as a major breakthrough that could save lives, lessen pain and suffering, and cut back on the billions spent annually in healthcare costs to manage stroke."

Stroke is the third major cause of death in the United States. According to the American Heart Association, about 700,000 people each year experience a new or recurrent stroke in the United States, resulting in an estimated 5.7 million stroke patients with an estimated direct and indirect cost to treat and care for these patients of $62.7 billion in 2007.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with human FGF-1 as their active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has three clinical trials underway with drug candidates to treat the following medical indications: severe Coronary Heart Disease (CVBT-141A), dermal wound healing in diabetics (CVBT-141B), and Peripheral Arterial Disease (CVBT-141C).

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category